Closed Loop Medicine Secures $15M Series A to Transform Precision Care for Chronic Diseases

Closed Loop Medicine is thrilled to announce that we have successfully raised $15,000,000 to accelerate our mission of transforming healthcare by putting the individual at the forefront of treatment. As a groundbreaking TechBio company, we are dedicated to shifting the paradigm from treating diseases in isolation to embracing a holistic approach that addresses the unique health needs of each patient. Our leading-edge combination of prescription drugs and innovative software solutions is designed to deliver personalized, optimized dosing, ensuring that every patient receives care tailored specifically to their genetic profile and lifestyle. This infusion of capital will significantly bolster our efforts to refine and expand our proprietary technology platform, which seamlessly integrates medicines with advanced software and patient-led digital experiences. By leveraging closed loop models of care, we are not only setting new benchmarks in precision medicine but also paving the way for universal healthcare access that is truly bespoke and outcome-oriented. The funding will enable us to further develop our suite of innovative products, advance clinical studies, and deepen strategic partnerships with healthcare providers and technology leaders around the globe. As we press forward in our journey toward realizing the promise of precision care for all, we remain committed to enhancing outcomes for patients with chronic diseases by ensuring that every treatment is as unique as the person receiving it. To learn more about our mission and the exciting innovations driving our work, please visit www.closedloopmedicine.com. Join us as we lead the charge in a revolution where personalized medicine is not just a vision, but a reality for everyone.